These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 9713785

  • 1. Change in intraocular pressure during long-term use of loteprednol etabonate.
    Novack GD, Howes J, Crockett RS, Sherwood MB.
    J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
    [Abstract] [Full Text] [Related]

  • 2. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
    Holland EJ, Djalilian AR, Sanderson JP.
    Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG, Lothringer LL, Rubin JM, Briggs RB, Howes J, Novack GD, Hart K.
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [Abstract] [Full Text] [Related]

  • 4. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
    Rajpal RK, Digby D, D'Aversa G, Mah F, Hollander DA, Conway T.
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
    [Abstract] [Full Text] [Related]

  • 5. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
    Lane SS, Holland EJ.
    J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
    [Abstract] [Full Text] [Related]

  • 6. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
    Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL.
    Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
    [Abstract] [Full Text] [Related]

  • 7. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
    Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
    [Abstract] [Full Text] [Related]

  • 8. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M, Howes J, George M.
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
    Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M.
    Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
    [Abstract] [Full Text] [Related]

  • 10. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial.
    Price MO, Feng MT, Scanameo A, Price FW.
    Cornea; 2015 Aug; 34(8):853-8. PubMed ID: 26020827
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK, Roel L, Siou-Mermet R, Erb T.
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [Abstract] [Full Text] [Related]

  • 12. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
    Noble S, Goa KL.
    BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
    [Abstract] [Full Text] [Related]

  • 13. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
    Friedlaender MH, Howes J.
    Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
    [Abstract] [Full Text] [Related]

  • 14. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
    Asbell P, Howes J.
    CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
    [Abstract] [Full Text] [Related]

  • 15. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
    Sheppard JD, Comstock TL, Cavet ME.
    Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
    [Abstract] [Full Text] [Related]

  • 16. Loteprednol etabonate: a review of ophthalmic clinical studies.
    Howes JF.
    Pharmazie; 2000 Mar; 55(3):178-83. PubMed ID: 10756536
    [Abstract] [Full Text] [Related]

  • 17. Treatment of ocular inflammatory conditions with loteprednol etabonate.
    Pavesio CE, Decory HH.
    Br J Ophthalmol; 2008 Apr; 92(4):455-9. PubMed ID: 18245274
    [Abstract] [Full Text] [Related]

  • 18. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
    Stewart R, Horwitz B, Howes J, Novack GD, Hart K.
    J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
    [Abstract] [Full Text] [Related]

  • 19. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
    Dell SJ, Shulman DG, Lowry GM, Howes J.
    Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
    [Abstract] [Full Text] [Related]

  • 20. Intraocular pressure response to loteprednol etabonate in known steroid responders.
    Bartlett JD, Horwitz B, Laibovitz R, Howes JF.
    J Ocul Pharmacol; 1993 Jun; 9(2):157-65. PubMed ID: 8345288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.